Published in Clin Transl Oncol on June 01, 2010
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One (2013) 0.93
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One (2013) 0.89
STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist (2014) 0.88
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma. Oncologist (2012) 0.80
Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma. Cancer Biol Med (2012) 0.79
Reciprocal occupancy of BCL6 and STAT5 on Growth Hormone target genes: contrasting transcriptional outcomes and promoter-specific roles of p300 and HDAC3. Mol Cell Endocrinol (2014) 0.76
Intravascular large B-cell lymphoma: report of three cases and analysis of the mTOR pathway. Int J Clin Exp Pathol (2011) 0.75
Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma. Oncotarget (2017) 0.75
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Invest New Drugs (2015) 0.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 2.81
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 2.77
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol (2012) 2.25
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer (2003) 2.21
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol (2006) 1.60
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood (2004) 1.49
Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma (2011) 1.46
Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J (2002) 1.45
Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother (2011) 1.41
International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer (2002) 1.36
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res (2011) 1.14
How important is whole brain radiotherapy for treatment of primary CNS lymphoma? Lancet Oncol (2010) 1.11
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer (2008) 1.02
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer (2006) 1.01
Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am J Clin Pathol (2002) 0.98
CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol (2002) 0.96
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 0.93
An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer (2002) 0.92
Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol (2007) 0.92
Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res (2003) 0.91
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood (2002) 0.89
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol (2006) 0.87
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res (2003) 0.87
Quantitative assessment of disease involvement by follicular lymphoma using real-time polymerase chain reaction measurement of t(14;18)-carrying cells. Int J Hematol (2004) 0.86
Recent advances in the management of mantle cell lymphoma. Curr Opin Oncol (2013) 0.86
Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico. Cancer Med (2013) 0.84
Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol (2002) 0.84
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol (2004) 0.83
Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma (2002) 0.83
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.82
The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist (2005) 0.82
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma (2004) 0.81
Thalidomide for patients with recurrent lymphoma. Cancer (2004) 0.81
Aleukemic leukemia cutis preceding acute monocytic leukemia: a case report. P R Health Sci J (2008) 0.81
Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys (2003) 0.80
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options. Hematology Am Soc Hematol Educ Program (2000) 0.80
Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer (2002) 0.80
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations. Lab Invest (2003) 0.79
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature. P R Health Sci J (2009) 0.79
Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practice. Cancer (2004) 0.79
Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma. Leuk Lymphoma (2002) 0.79
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer (2005) 0.79
BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res (2002) 0.78
Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study. BMC Infect Dis (2013) 0.78
Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab. J Clin Oncol (2011) 0.77
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol (2002) 0.77
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys (2003) 0.77
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma (2006) 0.77
Establishment and characterization of a new mantle cell lymphoma cell line M-1. Leuk Lymphoma (2004) 0.77
Triple negative breast cancer: a retrospective study of Hispanics residing in Puerto Rico. P R Health Sci J (2012) 0.76
Therapeutic concepts in mantle cell lymphoma. Eur J Haematol (2010) 0.76
Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico. P R Health Sci J (2010) 0.76
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. Br J Haematol (2014) 0.76
Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. Int J Radiat Oncol Biol Phys (2003) 0.76
Reply to I.E. Haines. J Clin Oncol (2013) 0.75
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol (2002) 0.75
Diffuse large-cell lymphoma. Part I: clinical features, histology and prognosis. P R Health Sci J (2009) 0.75
Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer J (2003) 0.75
Diffuse large-cell lymphoma. Part II: management. P R Health Sci J (2009) 0.75
A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. Int J Radiat Oncol Biol Phys (2005) 0.75
Clinical and pathological features of colorectal cancer in patients at a community hospital in Puerto Rico. P R Health Sci J (2014) 0.75
Development of microsatellite markers for Anadenanthera colubrina var. cebil (Fabaceae), a native tree from South America. Am J Bot (2012) 0.75
A proposed approach for the selection of the proper surgical therapy to obtain an adequate margin of resection in locally advanced ultra-low rectal cancer after modern preoperative CRX management. Bol Asoc Med P R (2009) 0.75
Severe anemia of rapid onset in an inmunocompromised host. Bol Asoc Med P R (2009) 0.75
Metastatic Ovarian Tumor Masquerading as Atypical Pneumonia. Bol Asoc Med P R (2016) 0.75
POEMS Syndrome: A Rare Disease With A Challenging Diagnosis. Bol Asoc Med P R (2016) 0.75